Table 4.

Summary of the relevant randomized trials evaluating hypofractionation of radiation therapy.

Study (year)	Patient population	Treatment	Results	Ref.
Yarnold et al. (2005) Owen et al. (2006) RMH/GOC	1410 patients (T stage 1–3 with a max of one + node)	Gy/fx#/fx dose/#patients 50/25/2.0 (470) 42.9/13/3.3 (466) 39/13/3.0 (474)	Median fu 9.7 years, 12% local recurrence 10% 15%	[79,80]
Whelan et al. (2002), (2010) OCOG	1234 patients LN negative margin negative breast ca	Gy/fx#/fx dose/#patients 50/25/2.0 (612) 42.5/16/2.66 (622)	10 year local recurrence 6.7% 6.2% No difference in cosmesis, survival	[81,82]
Bentzen et al. (2008) Haviland et al. (2013) START A	2236 patients with breast cancer (pT1–3a pN0–1)	Gy/fx#/fx dose/#patients 50/25/2.0 (749) 41.6/13/3.2 (750) 39/13/3.0 (737)	Median fu 9.3 years, 7% local recurrence 6% 9%. No difference in late toxicity or survival	[83,84]
Bentzen et al. (2008) Haviland et al. (2013) START B	2215 patients with breast cancer (pT1–3a pN0–1)	Gy/fx#/fx dose/#patients 50/25/2.0 (1105) 40/15/2.67 (1110)	Median fu 9.9 years, 6% local recurrence 4%. No difference in late toxicity or survival	[84–85]

#: Number; ca: Cancer; fx: Fraction; fu: Follow-up; Gy: Gray; LN: Lymph node.